Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Celgene Corporation stock (CELG)

Buy Celgene Corporation stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Celgene Corporation is a drug manufacturers - general business based in the US. Celgene Corporation shares (CELG) are listed on the NASDAQ and all prices are listed in US Dollars. Celgene Corporation employs 8,852 staff and has a trailing 12-month revenue of around $17 billion.

Our top picks for where to buy Celgene Corporation stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for cash sweep

Go to site
Advanced charts and trading tools
  • Trade stocks, ETFs and equity options without commission and $0 option contract fees
  • Earn up to 8.1% APY on your uninvested cash
  • Get a 1.5% match in cash on transferred assets up to $300 or up to 15 free fractional shares worth between $2 and $2,000

How to buy Celgene Corporation stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – CELG. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Celgene Corporation stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Moomoo
Finder Score: 4.3 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Public.com
Finder Score: 4.2 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
5.1%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Celgene Corporation stock price (NASDAQ: CELG)

Use our graph to track the performance of CELG stocks over time.

Celgene Corporation shares at a glance

Information last updated 2020-04-13.
52-week range$0.00 - $0.00
50-day moving average $108.24
200-day moving average $104.36
Wall St. target price$103.40
PE ratio 13.33
Dividend yield N/A (0%)
Earnings per share (TTM) $8.13

Is it a good time to buy Celgene Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Celgene Corporation stock undervalued or overvalued?

Valuing Celgene Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Celgene Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Celgene Corporation's P/E ratio

Celgene Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Celgene Corporation shares trade at around 13x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Celgene Corporation's PEG ratio

Celgene Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.86. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Celgene Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Celgene Corporation's EBITDA

Celgene Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.9 billion.

The EBITDA is a measure of a Celgene Corporation's overall financial performance and is widely used to measure a its profitability.

Celgene Corporation financials

Revenue TTM $17 billion
Operating margin TTM 48.75%
Gross profit TTM $14.1 billion
Return on assets TTM 13.69%
Return on equity TTM 69.39%
Profit margin 34.63%
Book value $16.99
Market Capitalization $77 billion

TTM: trailing 12 months

Celgene Corporation share dividends

We're not expecting Celgene Corporation to pay a dividend over the next 12 months.

Have Celgene Corporation's shares ever split?

Celgene Corporation's shares were split on a 2:1 basis on 25 June 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Celgene Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Celgene Corporation shares which in turn could have impacted Celgene Corporation's share price.

Celgene Corporation share price volatility

Over the last 12 months, Celgene Corporation's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

CELG.US volatility(beta: 1.41)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celgene Corporation's is 1.4131. This would suggest that Celgene Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Celgene Corporation overview

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc. ; Agios Pharmaceuticals, Inc. ; bluebird bio, Inc.

Frequently asked questions

What percentage of Celgene Corporation is owned by institutions?
Currently 78% of Celgene Corporation shares are held by institutions.
How many people work for Celgene Corporation?
Latest data suggests 8,852 work at Celgene Corporation.
When does the fiscal year end for Celgene Corporation?
Celgene Corporation's fiscal year ends in December.
Where is Celgene Corporation based?
Celgene Corporation's address is: 86 Morris Avenue, Summit, NJ, United States, 07901
What is Celgene Corporation's ISIN number?
Celgene Corporation's international securities identification number is: US1510201049
What is Celgene Corporation's CUSIP number?
Celgene Corporation's Committee on Uniform Securities Identification Procedures number is: 151020104

More guides on Finder

Ask a Question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site